Lara Bossini-Castillo,
Carmen P Simeon,
Lorenzo Beretta,
Madelon C Vonk,
José Luis Callejas-Rubio,
Gerard Espinosa,
Patricia Carreira,
María T Camps,
Luis Rodríguez-Rodríguez, Mónica Rodríguez-Carballeira, [......],
Paul Shiels,
Jacob M van Laar,
Carmen Fonseca,
Christopher Denton,
Ariane Herrick,
Jane Worthington,
Bobby P Koeleman,
Blanca Rueda,
Timothy R D J Radstake,
Javier Martin
[show abstract]
[hide abstract]
ABSTRACT: The aim of this study was to confirm the implication of macrophage migration inhibitory factor (MIF) gene in SSc susceptibility or clinical phenotypes in a large European population.
A total of 3800 SSc patients and 4282 healthy controls of white Caucasian ancestry from eight different European countries were included in the study. The MIF -173 single nucleotide polymorphism (SNP) was selected as genetic marker and genotyped using Taqman 5' allelic discrimination assay.
The MIF -173 SNP showed association with SSc [P = 0.04, odds ratio (OR) = 1.10, 95% CI 1.00, 1.19]. Analysis of the MIF -173 polymorphism according to SSc clinical phenotype revealed that the frequency of the -173*C allele was significantly higher in the dcSSc group compared with controls (P = 5.30E-03, OR = 1.21, 95% CI 1.07, 1.38). Conversely, the frequency of the MIF -173*C allele was significantly underrepresented in the lcSSc group compared with dcSSc patients, supporting previous findings [(P = 0.04, OR = 0.86, 95% CI 0.75, 0.99); meta-analysis including previous results (P = 0.005, OR = 0.83, 95% CI 0.73, 0.94)].
Our results confirm the role of MIF -173 promoter polymorphism in SSc, and provide evidence of a strong association with the dcSSc subgroup of patients. Hence, the MIF -173 variant is confirmed as a promising clinical phenotype genetic marker.
Rheumatology (Oxford, England) 08/2011; 50(11):1976-81. · 4.24 Impact Factor
